Back to today’s briefing

Story perspectives

New Treatment Extends ALS Life by 74% in Mice

7/15/2025

26 2

Summary

Story summary

A groundbreaking treatment, Multipath Direct Current Stimulation (DCS), has demonstrated remarkable potential in slowing ALS progression, with treated mice living 74% longer than their untreated counterparts. By reducing abnormal nerve activity and safeguarding motor neurons, this noninvasive therapy offers hope. Pathmaker Neurosystems is now advancing to human clinical trials, aiming to transform ALS treatment.

1 of 1

Story summary

A groundbreaking treatment, Multipath Direct Current Stimulation (DCS), has demonstrated remarkable potential in slowing ALS progression, with treated mice living 74% longer than their untreated counterparts. By reducing abnormal nerve activity and safeguarding motor neurons, this noninvasive therapy offers hope. Pathmaker Neurosystems is now advancing to human clinical trials, aiming to transform ALS treatment.